

Dcaf7 antibody - N-terminal region

Rabbit Polyclonal Antibody

Catalog # AI13371

Product Information

Application	WB
Primary Accession	P61963
Other Accession	NM_027946 , NP_082222
Reactivity	Human, Mouse, Rat, Rabbit, Zebrafish, Pig, Dog, Guinea Pig, Horse, Bovine
Predicted	Human, Mouse, Rat, Zebrafish, Pig, Chicken, Guinea Pig, Horse, Bovine
Host	Rabbit
Clonality	Polyclonal
Calculated MW	38926

Additional Information

Gene ID	71833
Alias Symbol	1700012F10Rik, 2610037L01Rik, C86529, HAN11, Wdr68
Other Names	DDB1- and CUL4-associated factor 7, WD repeat-containing protein 68, WD repeat-containing protein An11 homolog, Dcaf7, Han11, Wdr68
Format	Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Reconstitution & Storage	Add 50 ul of distilled water. Final anti-Dcaf7 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.
Precautions	Dcaf7 antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	Dcaf7
Synonyms	Han11, Wdr68
Function	Involved in craniofacial development. Acts upstream of the EDN1 pathway and is required for formation of the upper jaw equivalent, the palatoquadrate. The activity required for EDN1 pathway function differs between the first and second arches. Associates with DIAPH1 and controls GLI1 transcriptional activity. Could be involved in skin development. May function as a substrate receptor for CUL4-DDB1 E3 ubiquitin-protein ligase complex (By similarity).


Cellular Location

Cytoplasm. Nucleus. Note=Overexpression of DIAHP1 or active RHOA causes translocation from the nucleus to cytoplasm

References

Carninci P.,et al.Science 309:1559-1563(2005).
Morita K.,et al.J. Dermatol. Sci. 44:11-20(2006).

Images



WB Suggested Anti-Dcaf7 Antibody Titration: 1.0 µg/ml
Positive Control: Mouse Spleen

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.